1. Home
  2. REED vs NSRX Comparison

REED vs NSRX Comparison

Compare REED & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

REED

Reed's Inc.

N/A

Current Price

$1.73

Market Cap

29.6M

Sector

N/A

ML Signal

N/A

NSRX

Nasus Pharma Ltd. Ordinary Shares

HOLD

Current Price

$3.15

Market Cap

32.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REED
NSRX
Founded
1987
2019
Country
United States
Israel
Employees
44
7
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.6M
32.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
REED
NSRX
Price
$1.73
$3.15
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$19.67
AVG Volume (30 Days)
31.1K
52.6K
Earning Date
05-12-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$18.74
N/A
Revenue Next Year
$18.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.42
$1.98
52 Week High
$5.97
$9.99

Technical Indicators

Market Signals
Indicator
REED
NSRX
Relative Strength Index (RSI) 31.11 55.63
Support Level N/A $2.04
Resistance Level $2.67 $3.48
Average True Range (ATR) 0.35 0.25
MACD -0.03 0.02
Stochastic Oscillator 17.21 68.83

Price Performance

Historical Comparison
REED
NSRX

About REED Reed's Inc.

Reed's Inc is a branded beverage company offering a portfolio of natural, premium, and functional beverages under the Reed's and Virgil's brands. The company's portfolio of handcrafted, all-natural beverages is sold in outlets nationwide, including the natural and specialty food channel, grocery stores, mass merchants, drug stores, convenience stores, club stores, and on-premise locations, including bars and restaurants. The company operates in a single reportable segment, which consists of manufacturing carbonated beverages under Reed's and Virgil's brand names.

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Share on Social Networks: